Harrow Health, Inc. (HROW) 

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Show less

Over the last 12 months, insiders at Harrow Health, Inc. have bought $2.94M and sold $0 worth of Harrow Health, Inc. stock.

On average, over the past 5 years, insiders at Harrow Health, Inc. have bought $2.11M and sold $308,658 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Opaleye Management Inc. (10 percent owner) — $11.68M. BAUM MARK L (Chief Executive Officer) — $528,050. Makary Martin A. (director) — $338,400.

The last purchase of 20,000 shares for transaction amount of $199,400 was made by Opaleye Management Inc. (10 percent owner) on 2024‑04‑25.